A sucrose isomerase mutant with specific sucrose conversion capabilities and its applications

By performing targeted mutations on sucrose isomerase, particularly by replacing the amino acids F245L and K286V, the conversion rate and enzyme activity of sucrose isomerase were improved, solving the problems of high production cost and difficult separation and purification in existing technologies, and achieving efficient production of isomaltulose.

CN117487791BActive Publication Date: 2026-11-17INST OF BOTANY CHINESE ACAD OF SCI
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202311436873.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-01
Publication Date
2026-11-17
Estimated Expiration
2043-11-01

AI Technical Summary

Technical Problem

Existing sucrose isomerases have low enzyme utilization and unavoidable byproducts in the production of isomaltulose, resulting in high production costs. Furthermore, downstream separation and purification are difficult, which limits the widespread application of isomaltulose.

Method used

By performing targeted mutations on wild-type sucrose isomerase, specifically mutating amino acid 245 from phenylalanine to leucine and amino acid 286 from lysine to valine, a sucrose isomerase mutant with specific sucrose conversion capabilities was obtained and expressed in Escherichia coli, thereby improving its conversion rate and enzyme activity.

Benefits of technology

It significantly improves the conversion rate and enzyme activity of sucrose isomerase, increases substrate conversion rate to 80%, reduces production costs, and is suitable for large-scale industrial production of isomaltulose.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

This invention relates to a sucrose isomerase mutant with specific sucrose conversion capabilities and its applications, belonging to the field of genetic engineering technology. This invention obtained two sucrose isomerase mutants, F245L+K286V and F245L, with specific sucrose conversion capabilities through random mutation. Expression of the genes encoding these mutants in an *E. coli* expression system significantly improved the specificity and conversion rate of the resulting sucrose isomerase mutants. These two sucrose isomerase mutants are biocatalysts that can be applied in the industrial production of isomaltulose to improve production efficiency, shorten the fermentation cycle, and reduce production costs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a sucrose isomerase mutant with specific sucrose conversion properties and its applications, belonging to the field of genetic engineering technology. Background Technology

[0002] Isomaltulose, also known as palaginose, has the molecular formula C64. 12 H 22 O 11 Isomaltulose is an isomer of sucrose and is a reducing sugar. As a functional disaccharide, isomaltulose has 52% the sweetness of sucrose, and therefore can be used as a novel sweetener to replace sucrose.

[0003] The US FDA has approved isomaltulose as a safe food additive with no intake restrictions. Its physicochemical properties and physiological functions allow isomaltulose to be widely used as a substitute for sucrose in functional beverages, weight-loss supplements, and foods for diabetics. Currently, more than 40 countries and regions worldwide have begun using isomaltulose as a food additive to replace sucrose, with Europe, the US, and Japan being the largest users, consuming 100,000 tons in 2009. In my country, the demand for isomaltulose is large, but domestic industrial production of isomaltulose started late and has low capacity. Therefore, the required products mainly rely on imports from Germany and Japan, with the market price of this sugar at 15,000 yuan / ton.

[0004] Isomaltulose is extremely rare in nature, existing only in small amounts in honey and sugarcane juice, making direct extraction methods unsuitable. Currently, the main methods for isomaltulose synthesis reported in the literature include: chemical synthesis, in vivo plant transformation, microbial cell transformation, and sucrose isomerase conversion. Chemical synthesis is costly and polluting, in vivo plant transformation can lead to plant stagnation, and microbial cell transformation offers high yields but suffers from complex fermentation broth composition, making subsequent separation and purification somewhat difficult. Therefore, the optimal method for producing isomaltulose is currently the sucrose isomerase conversion method.

[0005] Sucrose isomerase, also known as α-glucosyltransferase, is an enzyme that converts sucrose into isomaltulose and trehalose, producing a small amount of monosaccharides. The catalytic mechanism of sucrose isomerase involves nucleophilic attack on sucrose, causing the α1-β1 glycosidic bond to break and the fructose group to orient; isomerization or hydrolysis occurs.

[0006] Achieving high-yield, high-purity, and low-cost production of isomaltulose using sucrose isomerases has always been a research direction. In the production of isomaltulose using sucrose isomerases, low enzyme utilization and unavoidable byproducts are two significant disadvantages, keeping the production cost of isomaltulose high and limiting its substitution for sucrose. Compared to the monosaccharide byproducts, the use of sucrose isomerases produces another sucrose isomer—trehalose. Due to its structural similarity to isomaltulose, downstream separation and purification are more difficult; industrially, recrystallization is generally used to separate trehalose and isomaltulose. Higher isomaltulose conversion rates mean that the production process can achieve higher isomaltulose yields or produce isomaltulose products with higher purity. Simultaneously, increasing the enzyme activity of sucrose isomerase can improve production efficiency and reduce production costs.

[0007] To obtain more efficient biocatalysts, screening for new sucrose isomerases that may have high efficiency in generating isomaltulose is a key task at present. Summary of the Invention

[0008] To overcome the shortcomings of the existing technology, the present invention provides a sucrose isomerase mutant that can specifically convert sucrose into isomaltulose, with a conversion rate that greatly exceeds that of wild-type sucrose isomerase.

[0009] The present invention also provides the mutant transformed engineered strain.

[0010] Another object of the present invention is to provide the use of this mutant in the production of isomaltulose.

[0011] The technical solution adopted in this invention is as follows.

[0012] The first objective of this invention is to provide a sucrose isomerase mutant that specifically converts sucrose, the amino acid sequence of which is shown in either SEQ ID NO.4 or SEQ ID NO.6.

[0013] The sucrose isomerase mutant was obtained by performing any of the following localization mutations on the sucrose isomerase, whose starting amino acid sequence is shown in SEQ ID NO.2:

[0014] The amino acid at position 245 is mutated from phenylalanine to leucine, resulting in mutant F245L. The amino acid sequence of the mutant is shown in SEQ ID NO.4.

[0015] The amino acid at position 245 is mutated from phenylalanine to leucine, and the amino acid at position 286 is mutated from lysine to valine, resulting in the mutant F245L+K286V. The amino acid sequence of the mutant is shown in SEQ ID NO.6.

[0016] Another object of the present invention is to provide a gene encoding a sucrose isomerase mutant, the nucleotide sequence of which includes any of the following:

[0017] a) The base sequence shown in any one of SEQ ID NO.1, SEQ ID NO.3, or SEQ ID NO.5; b) The protein encoding an amino acid sequence shown in any one of SEQ ID NO.2, SEQ ID NO.4, or SEQ ID NO.6, or a nonsense mutant sequence thereof.

[0018] In one embodiment of the present invention, the nucleotide sequence of the gene is obtained by gene synthesis from the template nucleotide sequence shown in SEQ ID NO.1, and the primers corresponding to the PCR amplification are shown in Table 1.

[0019] Another object of the present invention is to provide a recombinant expression plasmid for encoding a sucrose isomerase mutant, containing the above-mentioned nucleotide sequence, and the expression vector comprising pLacO1, SacB, Amp, and pBR322.

[0020] Another object of the present invention is to provide an engineered strain expressing sucrose isomerase, said engineered strain being capable of producing the above-mentioned sucrose isomerase mutant, or integrating the gene of the above-mentioned sucrose isomerase mutant, or containing the above-mentioned recombinant expression plasmid.

[0021] In one embodiment of the present invention, the engineered strain uses host microorganisms, including Escherichia coli and Corynebacterium glutamicum, as competent cells.

[0022] In one embodiment of the present invention, the host is Escherichia coli BL21(DE3).

[0023] Another objective of this invention is to provide a crude enzyme solution of a sucrose isomerase mutant, obtained by selecting positive monoclonal strains from the above-mentioned engineered strains for enrichment culture, and then separating and filtering the resulting crude enzyme solution of the sucrose isomerase mutant.

[0024] In one embodiment of the present invention, the fermentation conditions are: fermentation temperature 30°C and fermentation time 48h.

[0025] Another object of the present invention is to provide the application of the above-mentioned engineered strain expressing sucrose isomerase or the above-mentioned crude enzyme solution of sucrose isomerase mutant, specifically as a biocatalyst for catalyzing the synthesis of isomaltulose.

[0026] In one embodiment of the present invention, in the reaction system for catalyzing isomaltulose synthesis, the substrate concentration is 300 g / L and the bacterial load is 10 g / L. 9 count / mL, temperature 30℃.

[0027] In one embodiment of the present invention, in the reaction system for catalyzing the synthesis of isomaltulose, the fermentation temperature is 30°C and the mixture is incubated on a shaker at 220 rpm.

[0028] The beneficial effects of this invention are:

[0029] (1) In this invention, the wild-type sucrose isomerase gene synthesized by error-prone PCR is randomly mutated to obtain a gene library encoding mutants, which are then expressed and screened in an E. coli expression system. The resulting sucrose isomerase mutants have significantly improved activity and conversion rate.

[0030] (2) The sucrose isomerase mutant prepared by this invention is a biocatalyst. Its application in the industrial production of isomaltulose can improve production efficiency and reduce production costs. In the process of preparing isomaltulose, the substrate conversion rate is effectively increased to 80%, which is more than 50% higher than that of wild-type strains.

[0031] (3) The sucrose isomerase mutant prepared in this invention can be used as a biocatalyst to increase the substrate concentration to 350 g / L in the industrial production of isomaltulose, which is suitable for large-scale industrial production and has broad prospects for practical production applications. Attached Figure Description

[0032] Figure 1 Here is the structure diagram of the pTD-176B plasmid.

[0033] Figure 2 Growth tests to screen sucrose concentration conditions;

[0034] Figure 3 The chromatogram is for 2.5 g / L MIX (two standard sugar solutions, each 2.5 g / L).

[0035] Sucrose elutes first with a retention time of 10.144 min; isomaltulose elutes later with a retention time of 10.877 min; the solvent peak is at 3.298 min.

[0036] Figure 4 The results are obtained by HPLC analysis of the products after 96 hours of shake-flask fermentation of WT strain (original sucrose isomerase).

[0037] Figure 5 The results are obtained by HPLC analysis of the products from shake-flask fermentation of strain F245 (a sucrose isomerase mutant) after 96 hours.

[0038] Figure 6 The results are for the product analysis after 96 hours of shake-flask fermentation of strain F245L+K286V (sucrose isomerase mutant).

[0039] Figure 7 The results are for the 24-hour product detection of crude enzyme solution from WT strain (original sucrose isomerase).

[0040] Figure 8 The results are from the detection of the product of crude enzyme solution from strain F245 (sucrose isomerase mutant) after 24 hours.

[0041] Figure 9 To simulate the sucrose isomerization process, i.e., the HPLC peak area and concentration correspondence of sucrose isomerase catalyzing the conversion of sucrose into isomaltulose.

[0042] Figure 10 To simulate the HPLC detection chromatograms of sucrose and isomaltulose at different conversion rates during sucrose isomerization,

[0043] Figure 11 Isomaltulose yield and conversion rate in enzyme (crude enzyme solution) reactions between mutant F245L and wild-type sucrose isomerase.

[0044] Figure 12 The yield and conversion rate of isomaltulose by shake-flask fermentation of wild-type sucrose isomerase and mutant F245L / F245L+K286V. Detailed Implementation

[0045] This invention uses the coding sequence shown in SEQ ID NO.7 (derived from Pantoeadispersa UQ68J) as a template for codon optimization and adjustment (the optimized sequence is shown in SEQ ID NO.1). Then, using the primers shown in Table 1, gene synthesis is performed. Subsequently, error-prone PCR is performed using the correctly sequenced sequence as a template. The gene sequence of the sucrose isomerase mutant F245L+K286V / F245L is obtained through appropriate screening methods. The obtained gene sequence and the wild-type sucrose isomerase sequence are respectively ligated into the pTD176B expression vector to obtain recombinant plasmids pTD176(WT), pTD176(F245L), and pTD176(F245L+K286V). The recombinant plasmids are transformed into Escherichia coli BL21(DE3), and positive single clones are selected for fermentation culture.

[0046] The original gene sequence used in this invention, SEQ ID NO.7, is derived from Pantoeadispersa UQ68J, whose genome number in GenBank is AY223549.1. The gene is 1797 bp in length and contains 598 amino acids, as shown in SEQ ID NO.2.

[0047] The preferred embodiments of the present invention are described below. It should be understood that the embodiments are for better explanation of the present invention and are not intended to limit the present invention.

[0048] All the biological materials involved in this invention are preserved in the applicant's laboratory and can be publicly distributed.

[0049] The pTD176B construction involves inserting sacBpromoter+sacB between the AmpR promoter and pBR322 on the commercial vector pUC19. The pBR322 sequence was amplified from the commercial vector pUC19 using PCR with a primer pair (pBR322-F: aggggataacgcaggaaag and pBR322-R: ctcaagaagatcctttgatcttttctacactccgctatcgctacg) as fragment 1, and another primer pair (Amp-F: cgtagcgatagcggagtgtgttaccaatgcttaatcagtgagg and Amp-R: cgcggaacccctatttgtt) as fragment 2. Subsequently, the primer pair (PSacB+SacB)-F: gACGCGTGCTAGAGGCATAgcacatatacctgccgttcac and (PSacB+SacB)-R: The sacBpromoter+sacB fragment 3 was obtained from the genome amplification of the BS168 Bacillus subtilis strain in the laboratory. The three fragments were recovered by gel electrophoresis, and their concentrations were determined using a NanoDrop™ One / One C micro-UV-Vis spectrophotometer. The three fragments were ligated according to the standard Gibson ligation procedure. 10 μl of the ligation product was added to 100 μl of competent cells, gently mixed, and incubated on ice for 30 min. The centrifuge tube was then heat-shocked in a 42°C water bath for 60 sec, immediately removed, and incubated on ice for 2 min. 900 μl of preheated (37°C) SOC medium was added, and the mixture was inverted to mix. The mixture was then incubated at 37°C and 220 rpm for 45 min. Spread 100 μl of bacterial culture onto 100 μg / ml ampicillin LB agar plates and incubate overnight at 37°C. The next day, perform colony PCR verification using primer pairs F:gggtgagcaaaaacaggaa and R:ccacctctgacttgagcgtc. Select samples with correct band sizes for sequencing. After confirming accurate sequencing, preserve the target plasmid and the bacterial strain containing the target plasmid. The plasmid structure is shown in [link to plasmid structure]. Figure 1 As shown.

[0050] Example 1

[0051] A sucrose isomerase mutant with specific sucrose conversion capabilities and its applications are described below. The specific steps of its preparation method are as follows:

[0052] Gene synthesis of wild-type sucrose isomerase gene: The gene was synthesized using primer-bridging PCR splicing. Two rounds of PCR were employed, and the reaction systems are shown in Tables 2, 3, and 4. The wild-type sucrose isomerase gene was constructed into the expression vector pTD176B (see...). Figure 1 )superior.

[0053] The specific steps are as follows:

[0054] 1) First, the backbone was amplified from pTD176B using primer pairs pBR322-R:ctcaagaagatcctttgatcttttctgtcaattgttatccgctcacaatt and Amp-F: cgtagcgatagcggagtgtgttaccaatgcttaatcagtgagg. 2) A codon-optimized SIase wild-type gene was synthesized as an insert fragment using a two-step gene synthesis method, and the fragments were then gel-recovered. 3) Residual plasmids from the backbone were removed by incubation with DpnI, an endonuclease that only cleaves methylation sites, for 60 minutes to reduce false positives. 4) Subsequently, the two fragments were ligated according to the standard Gibson ligation procedure. The ligation product was transformed into competent cells, plated onto 100 μg / ml ampicillin LB agar plates, and incubated overnight at 37°C. 5) On the second day, use primers to perform colony PCR verification on F:caagcagcagattacgcgca and R: gttatctacacgacggggag. Select the correct band size for testing. After the sequencing is accurate, save the target plasmid and the strain containing the target plasmid.

[0055] Table 1 Synthetic primers used in the splicing method

[0056]

[0057]

[0058] Table 2: First-step system for primer-based PCR

[0059]

[0060] Table 3: Primer-based PCR system for the second step of primer bridging

[0061]

[0062] Table 4: Primer-based PCR procedure

[0063]

[0064] (2) Using the wild-type sucrose isomerase gene synthesized in (1) (confirmed by sequencing) as a template, error-prone PCR was performed to construct random mutations across the entire gene range. The error-prone PCR reaction system is shown in Tables 5 and 6; the error-prone PCR amplification conditions were: 95℃ pre-denaturation for 3 min, 95℃ denaturation for 1 min, 56℃ annealing for 1 min, 72℃ extension for 5 min, for 35 cycles, and finally incubation at 16℃. The PCR amplification products were detected by agarose gel electrophoresis, and the gel was excised and purified. (The upper primer in Table 5 is (F: CGAATTTCATTAAAGAGGAGAAAGGTACCATGTTCCTGAACGGTTTCAAAACC), and the lower primer is (R: ACACTCCGCTATCGCTACGTTAGTGATGGTGGTGGTGATG))

[0065] Table 5: Error-prone PCR reaction systems

[0066]

[0067] Table 6: 10 × dNTPs Unbalanced Mixture

[0068]

[0069] (3) The purified error-prone PCR amplification product was ligated to the vector backbone using Gibson assembly reagent (as described above, the backbone was amplified from pTD176B using primer pairs pBR322-R:ctcaagaagatcctttgatcttttctgtcaattgttatccgctcacaatt and Amp-F:cgtagcgatagcggagtgtgttaccaatgcttaatcagtgagg);) and transformed into E. coli DH5α competent cells. After liquid resuscitation, the experimental group was not plated. After culturing for 2 hours, ampicillin was added to a final concentration of 100ug / ml. When the OD reached approximately 600 to 1, the mixed plasmid of the mutant library was extracted. After 1ml of bacterial culture in the control group was resuscitated, 100ul was plated on an antibiotic plate. The colonies on the plate were counted the next day, and single colonies were picked for testing to estimate the library capacity and error rate.

[0070] In the control group, 401 colonies grew on a 100 μL antibiotic plate. Seven colonies were randomly selected from the plate and sent for Sanger sequencing, yielding an average mutation rate of approximately 3.86‰. During ligation, a total of 100 μL of ligation product was produced, with 10 μL of ligation product transformed into 100 μL of competent cells. Therefore, the mutant library capacity is approximately 401 * 10 * 10 = 4.01 * 10^6 cells / year. 4 indivual.

[0071] (4) The mutant library plasmid from (3) was transformed into Escherichia coli BL21(DE3) cells. After liquid resuscitation, no plates were plated. After culturing for 2 hours, ampicillin was added to a final concentration of 100 μg / ml. When the OD reached approximately 600 to 0.5, IPTG was added to induce the expression of the sucrose isomerase gene. After 3 hours of induction, the plasmid was plated at appropriate dilutions on resistant plates with sucrose concentrations of 0 g / L, 100 g / L, 150 g / L, 200 g / L, 250 g / L, 300 g / L, 350 g / L, and 400 g / L. The presence and number of colonies were counted. The results showed that the pTD176 plasmid (co-expressed wild-type SIase and sacB genes) could grow at sucrose concentrations below 300 g / L, but colonies could not grow at sucrose concentrations above 300 g / L. Therefore, 350 g / L sucrose resistance agar plates were chosen as the screening condition for the random mutant library of sucrose isomerase. The results are as follows: Figure 2 As shown.

[0072] (5) The mutant from (4) was sent for testing to obtain information on the sucrose isomerase mutation site. Subsequently, the single clone containing this sequence was cultured in LB liquid medium containing 100 μg / mL ampicillin for seed culture, and then transferred to M9 liquid medium containing 100 μg / mL ampicillin for expansion culture and induction at 30℃ for 48 h to obtain fermentation broth. The fermentation broth was centrifuged at 4℃ and 8000 rpm for 10 min, the cells were collected and ultrasonically disrupted, and the supernatant was passed through an aqueous membrane after centrifugation to obtain crude enzyme solution.

[0073] (6) Add crude enzyme solution to buffer solution containing 300 g / L sucrose substrate, incubate at 30°C on a shaker for 24 h, then centrifuge the supernatant and filter it through a 0.22 μm filter membrane into a liquid chromatography bottle. The high performance liquid chromatography system is equipped with an amino column Agilent Zorbax VC-NH2 (4.6×250 mm, 5 μm 100 Ã) and a differential refractive index display for the detection of isomaltulose and sucrose (mobile phase: acetonitrile:water = 3:1; flow rate 1 ml / min; isocratic elution).

[0074] like Figures 3-12 As shown, the identification results of the reaction products of wild-type WT and its sucrose isomerase mutant F245L confirm the successful conversion of isomaltulose. In addition, the identification results of the sucrose isomerase mutant F245L+K286V are similar to those of the reaction products of the sucrose isomerase mutant F245L, which also confirms the successful conversion of isomaltulose.

[0075] The comparison of maximum conversion rates in the examples and comparative products revealed that, compared to the wild-type sucrose isomerase, the maximum conversion rates of the mutant F245L / F245L+K286V were all increased by more than 50%. The sucrose isomerase mutant not only showed improved enzyme activity but also promoted the production of isomaltulose, indicating that the sucrose isomerase mutant has better application performance.

[0076] Although the present invention has been disclosed above with reference to preferred embodiments, it is not intended to limit the present invention. Anyone skilled in the art can make various modifications and alterations without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention should be determined by the claims.

Claims

1. A sucrose isomerase mutant with specific sucrose conversion capabilities, the amino acid sequences of which are shown in SEQ ID NO.4 or SEQ ID NO.6, and the mutants are named F245 and F245L+K286V, respectively.

2. The sucrose isomerase mutant with specific sucrose conversion according to claim 1, wherein the sucrose isomerase mutant is obtained by site-directed or random mutation of a starting sucrose isomerase, the amino acid sequence of which is shown in SEQ ID NO.2, wherein the 245th amino acid is mutated from phenylalanine to leucine to obtain mutant F245L; based on mutant F245L, the 286th amino acid is mutated from lysine to valine to obtain mutant F245L+K286V.

3. The sucrose isomerase mutant with specific sucrose conversion according to claim 2, wherein the nucleotide sequence encoding the gene for initiating the sucrose isomerase is shown in SEQ ID NO.1, and the nucleotide sequence is synthesized by splicing the synthetic primers in the table below; 。 4. A gene encoding the sucrose isomerase mutant of claim 1, wherein the nucleotide sequence is shown in SEQ ID NO.3 or SEQ ID NO.5, respectively, encoding mutants F245 and F245L+K286V.

5. An engineered strain expressing sucrose isomerase, characterized in that, A gene containing the sucrose isomerase mutant as described in claim 4.

6. The engineered strain expressing sucrose isomerase according to claim 5, wherein the engineered strain includes Escherichia coli, Corynebacterium glutamicum, and Bacillus subtilis.

7. A crude enzyme solution of a sucrose isomerase mutant, characterized in that, The engineered strain described in claim 5 was cultured, and the crude enzyme solution of the sucrose isomerase mutant was obtained by centrifugation and ultrasonic cell disruption.

8. The application of the sucrose isomerase mutant of claim 1 as a biocatalyst in the reaction of catalyzing the conversion of sucrose to isomaltulose, wherein the mutant is F245 or F245L+K286V.

9. The application according to claim 8, wherein the crude enzyme solution obtained in claim 7 is fermented together with the substrate sucrose, wherein the fermentation system has the following characteristics: substrate concentration of 300 g / L and inoculum dosage of 10 g / L. 9 count / mL, temperature 30℃.

Citation Information

Patent Citations

  • Sucrose isomerase mutant with improved thermal stability and catalytic efficiency

    CN104762286A

  • Sucrose isomerase mutant and method for producing isomaltulose

    CN105483107A